Ensign Peak Advisors
PRVL

Ensign Peak Advisors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Ensign Peak Advisors’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28,143
Closed -$286K – 1900
2020
Q3 		$286K Buy
+28,143
New +$378K ﹤0.01% 1628

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's PRVL Position: Q4 2020 in Review

Ensign Peak Advisors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 28,143 shares — an estimated $286K sold.

Ensign Peak Advisors first reported a position in PRVL in Q3 2020 and held it in 1 quarter. The position peaked at $286K in Q3 2020. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

  • Ensign Peak Advisors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 28,143 Prevail Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $286K.
  • Ensign Peak Advisors first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Ensign Peak Advisors's Prevail Therapeutics Inc. Common Stock position peaked at $286K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Ensign Peak Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.